Bristol-Myers Squibb Co (BMY)

Industry Drug Manufacturers - General

This stock can be held in an Investment ISA and an Investment Account

Sell

$52.41

Buy

$52.50

arrow-up$1.21 (+2.36%)

Prices updated at 13 Dec 2025, 00:52 EST

Prices minimum 15 mins delay

Prices in USD

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

S&P 500

-1.07%

NYSE

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - General

Chairman

Dr. Christopher S. Boerner, PhD

CEO

Dr. Christopher S. Boerner, PhD

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

34,100

Head office

Route 206 and Province Line Road

New Jersey

United States

08543

+1 609 252-4621

investor.relations@bms.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. Sandra Leung Executive Vice President and General Counsel	1.15m
Dr. Cristian Massacesi, M.D. Executive Vice President, Chief Medical Officer and Head of Development	-
Mr. Derica W. Rice Independent Director	0.15m
Mr. Michael R. McMullen Independent Director	0.06m
Ms. Phyllis R. Yale Independent Director	0.14m
Ms. Paula A. Price Independent Director	0.14m
Mr. Peter J. Arduini Independent Director	0.14m
Mr. David V. Elkins Executive Vice President and Chief Financial Officer	1.12m
Dr. Christopher S. Boerner, PhD Chairman of the Board and Chief Executive Officer	1.54m
Dr. Julia A. Haller, M.D. Independent Director	0.15m
Mr. Theodore R. Samuels Lead Independent Director	0.20m
Dr. Karen H. Vousden, PhD Independent Director	0.14m
Mr. Benjamin J. Hickey, M.B.A. President, RayzeBio Organization	-
Dr. Robert M. Plenge, M.D.,PhD Executive Vice President, Chief Research Officer and Head of Research	-
Dr. Manuel Hidalgo Medina, M.D.,PhD Independent Director	0.14m
Mr. Gregory Scott Meyers Executive Vice President, Chief Digital Officer and Chief Technology Officer	-
Ms. Karin Shanahan Executive Vice President, Global Product Development and Supply	1.01m
Dr. Deepak L. Bhatt, M.D.,M.P.H. Independent Director	0.14m
Mr. Adam Lenkowsky Executive Vice President and Chief Commercialization Officer	-
Ms. Cari Gallman Executive Vice President, Corporate Affairs	-
Ms. Lynelle Hoch President, Cell Therapy Organization	-
Ms. Amanda Ahn Poole Executive Vice President and Chief People Officer	-
Mr. Phil Holzer Senior Vice President, Principal Accounting Officer and Controller	-

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
Vanguard Group Inc	194,925,206
BlackRock Inc	175,515,165
JPMorgan Chase & Co	172,361,328
State Street Corp	96,595,232
Charles Schwab Investment Management Inc	73,040,323

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
31 Dec 2024	-
31 Dec 2024	-
31 Dec 2024	-
31 Dec 2024	-
04 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
01 Nov 2024	-
02 Oct 2024	-
02 Oct 2024	-
02 Oct 2024	-
30 Sep 2024	-
30 Sep 2024	-
30 Sep 2024	-
30 Sep 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.